Frank Dunphy

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

Frank V. Fossella, Russell F. DeVore, Ronald N. Kerr et al. · Journal of Clinical Oncology · 2000 · 1.4K citations

Medicine, Oncology, Pharmacology +10

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

Glenwood Goss, Chun‐Ming Tsai, Frances A. Shepherd et al. · The Lancet Oncology · 2016 · 643 citations

Medicine, Oncology, Pharmacotherapy +9

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

George R. Blumenschein, Egbert F. Smit, David Planchard et al. · Annals of Oncology · 2015 · 360 citations · Full text

Medicine, Oncology, Pharmacology +14

Head and Neck Cancers, Version 2.2014

David G. Pfister, Sharon A. Spencer, David M. Brizel et al. · Journal of the National Comprehensive Cancer Network · 2014 · 281 citations · Full text

Medicine, Oncology, Surgery +15

Head and Neck Cancers, Version 1.2015

David G. Pfister, Sharon A. Spencer, David M. Brizel et al. · Journal of the National Comprehensive Cancer Network · 2015 · 269 citations · Full text

Medicine, Oncology, Radiation Oncology +17